Takuji Okusaka

Four Cases of Pancreatic Acinar Cell Carcinoma Treated with Gemcitabine or S-1 as a Single Agent (2009)

Seki, Yoshitaka, Okusaka, Takuji, Ikeda, Masafumi, Morizane, Chigusa, Ueno, Hideki

Pancreatic acinar cell carcinoma (ACC) is a comparatively rare tumor and account for ∼1% of all cases of pancreatic cancer. Clinical presentation is usually related to either local spread or...

Predictive Factors of Outcome and Tumor Response to Systemic Chemotherapy in Patients with Metastatic Hepatocellular Carcinoma (2008)

Ikeda, Masafumi, Okusaka, Takuji, Ueno, Hideki, Morizane, Chigusa, Kojima, Yasushi, Iwasa, Satoru, ...

Objective Systemic chemotherapy is an important treatment modality for metastatic hepatocellular carcinoma (HCC); however, the predictive factors of outcome and tumor response have not been fully...

Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line Therapy (2008)

Tanaka, Tsutomu, Ikeda, Masafumi, Okusaka, Takuji, Ueno, Hideki, Morizane, Chigusa, Hagihara, Atsushi, ...

Objective The purpose of the retrospective analysis is to elucidate the treatment efficacy and toxicity as well as to identify prognostic factors in Japanese patients with advanced pancreatic cancer...

Phase II Study of Combination Chemotherapy with Gemcitabine and Cisplatin for Patients with Metastatic Pancreatic Cancer (2007)

Ueno, Hideki, Okusaka, Takuji, Ikeda, Masafumi, Morizane, Chigusa, Ogura, Takashi, Hagihara, Atsushi, ...

Objective The objectives of this study were to evaluate the efficacy and toxicity of combination chemotherapy with gemcitabine and cisplatin in patients with metastatic pancreatic cancer. Methods...

A Multi-center Retrospective Analysis of Survival Benefits of Chemotherapy for Unresectable Biliary Tract Cancer (2007)

Yonemoto, Naohiro, Furuse, Junji, Okusaka, Takuji, Yamao, Kenji, Funakoshi, Akihiro, Ohkawa, Shinichi, ...

Background This study examined the effect of five systemic chemotherapy regimens on survival in patients with unresectable biliary tract cancer (BTC) as compared with the best supportive care (BSC). ...

A Phase I/II Study of Combination Chemotherapy with Gemcitabine and 5-Fluorouracil for Advanced Pancreatic Cancer (2006)

Okusaka, Takuji, Ishii, Hiroshi, Funakoshi, Akihiro, Ueno, Hideki, Furuse, Junji, Sumii, Toshihiko

Background: In an effort to improve efficacy of single-agent gemcitabine in pancreatic cancer, several studies have examined the effects of 5-FU combined with gemcitabine. However, no studies to date...

Early Phase II Study of Uracil-Tegafur Plus Doxorubicin in Patients with Unresectable Advanced Biliary Tract Cancer (2006)

Furuse, Junji, Okusaka, Takuji, Funakoshi, Akihiro, Yamao, Kenji, Nagase, Michitaka, Ishii, Hiroshi, ...

Background: Standard chemotherapy for advanced biliary tract cancer has not been established. The purpose of this study was to evaluate the efficacy and toxicity of a combination chemotherapy of...

Early Phase II Study of Uracil-Tegafur Plus Doxorubicin in Patients with Unresectable Advanced Biliary Tract Cancer (2006)

Furuse, Junji, Okusaka, Takuji, Funakoshi, Akihiro, Yamao, Kenji, Nagase, Michitaka, Ishii, Hiroshi, ...

Background: Standard chemotherapy for advanced biliary tract cancer has not been established. The purpose of this study was to evaluate the efficacy and toxicity of a combination chemotherapy of...

A Phase I/II Study of Combination Chemotherapy with Gemcitabine and 5-Fluorouracil for Advanced Pancreatic Cancer (2006)

Okusaka, Takuji, Ishii, Hiroshi, Funakoshi, Akihiro, Ueno, Hideki, Furuse, Junji, Sumii, Toshihiko

Background: In an effort to improve efficacy of single-agent gemcitabine in pancreatic cancer, several studies have examined the effects of 5-FU combined with gemcitabine. However, no studies to date...

A Phase II Trial of Uracil-Tegafur (UFT) in Patients with Advanced Biliary Tract Carcinoma (2005)

Ikeda, Masafumi, Okusaka, Takuji, Ueno, Hideki, Morizane, Chigusa, Furuse, Junji, Ishii, Hiroshi

Background: Uracil-tegafur (UFT) has been reported to have broad antitumor activity in a variety of malignancies. However, its activity in biliary tract carcinoma has not been fully evaluated. The...

Phase I Study of Fixed Dose Rate Infusion of Gemcitabine in Patients with Unresectable Pancreatic Cancer (2005)

Furuse, Junji, Ishii, Hiroshi, Okusaka, Takuji, Nagase, Michitaka, Nakachi, Kohei, Ueno, Hideki, ...

Objective: The purpose of this study was to determine the feasible dose of gemcitabine when administered as a fixed dose rate infusion (10 mg/m2/min) on a weekly schedule to Japanese patients with...

A Phase II Trial of Uracil-Tegafur (UFT) in Patients with Advanced Biliary Tract Carcinoma (2005)

Ikeda, Masafumi, Okusaka, Takuji, Ueno, Hideki, Morizane, Chigusa, Furuse, Junji, Ishii, Hiroshi

Background: Uracil–tegafur (UFT) has been reported to have broad antitumor activity in a variety of malignancies. However, its activity in biliary tract carcinoma has not been fully evaluated. The...

Phase I Study of Fixed Dose Rate Infusion of Gemcitabine in Patients with Unresectable Pancreatic Cancer (2005)

Furuse, Junji, Ishii, Hiroshi, Okusaka, Takuji, Nagase, Michitaka, Nakachi, Kohei, Ueno, Hideki, ...

Objective: The purpose of this study was to determine the feasible dose of gemcitabine when administered as a fixed dose rate infusion (10 mg/m2/min) on a weekly schedule to Japanese patients...

A Phase II Trial of Uracil-Tegafur (UFT) in Patients with Advanced Biliary Tract Carcinoma (2005)

Ikeda, Masafumi, Okusaka, Takuji, Ueno, Hideki, Morizane, Chigusa, Furuse, Junji, Ishii, Hiroshi

Background: Uracil-tegafur (UFT) has been reported to have broad antitumor activity in a variety of malignancies. However, its activity in biliary tract carcinoma has not been fully evaluated. The...

Phase I Study of Fixed Dose Rate Infusion of Gemcitabine in Patients with Unresectable Pancreatic Cancer (2005)

Furuse, Junji, Ishii, Hiroshi, Okusaka, Takuji, Nagase, Michitaka, Nakachi, Kohei, Ueno, Hideki, ...

Objective: The purpose of this study was to determine the feasible dose of gemcitabine when administered as a fixed dose rate infusion (10 mg/m2/min) on a weekly schedule to Japanese patients with...

Prognostic Factors in Patients with Hepatocellular Carcinoma Treated by Transcatheter Arterial Embolization (2002)

Ikeda, Masafumi, Okada, Shuichi, Yamamoto, Seiichiro, Sato, Tosiya, Ueno, Hideki, Okusaka, Takuji, ...

Background: Transcatheter arterial embolization induces marked antitumor response in patients with hepatocellular carcinoma, but the survival benefit of transcatheter arterial embolization remains to...

Phase I Trial of Gemcitabine in Patients with Advanced Pancreatic Cancer (2001)

Okada, Shuichi, Ueno, Hideki, Okusaka, Takuji, Ikeda, Masafumi, Furuse, Junji, Maru, Yasushi

Background: Gemcitabine is the most promising new agent currently being tested in pancreatic cancer. The present study was conducted to confirm the tolerability of a weekly schedule of gemcitabine at...

Spontaneous Regression of Hepatocellular Carcinoma with Multiple Lung Metastases: a Case Report (2001)

Ikeda, Masafumi, Okada, Shuichi, Ueno, Hideki, Okusaka, Takuji, Kuriyama, Hitoshi

Spontaneous regression of hepatocellular carcinoma is an extraordinarily unusual phenomenon. We present here a case of a 75-year-old man in whom multiple lung metastases of hepatocellular carcinoma...

Radiofrequency Ablation and Percutaneous Ethanol Injection in Patients with Small Hepatocellular Carcinoma: a Comparative Study (2001)

Ikeda, Masafumi, Okada, Shuichi, Ueno, Hideki, Okusaka, Takuji, Kuriyama, Hitoshi

Background: Radiofrequency ablation (RFA) is a novel thermal ablation technique to achieve coagulative necrosis of hepatocellular carcinoma. A study was conducted to compare the antitumor effect and...